A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.
Publication
, Conference
Coleman, RL; Enserro, D; Spirtos, N; Herzog, TJ; Sabbatini, P; Armstrong, DK; Kim, B; Fujiwara, K; Walker, JL; Flynn, PJ; Secord, AA; Cohn, DE ...
Published in: Journal of Clinical Oncology
May 20, 2018
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
5501 / 5501
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Coleman, R. L., Enserro, D., Spirtos, N., Herzog, T. J., Sabbatini, P., Armstrong, D. K., … Mannel, R. S. (2018). A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. In Journal of Clinical Oncology (Vol. 36, pp. 5501–5501). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.5501
Coleman, Robert L., Danielle Enserro, Nick Spirtos, Thomas J. Herzog, Paul Sabbatini, Deborah Kay Armstrong, Byoung Kim, et al. “A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.” In Journal of Clinical Oncology, 36:5501–5501. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.5501.
Coleman RL, Enserro D, Spirtos N, Herzog TJ, Sabbatini P, Armstrong DK, et al. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5501–5501.
Coleman, Robert L., et al. “A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 5501–5501. Crossref, doi:10.1200/jco.2018.36.15_suppl.5501.
Coleman RL, Enserro D, Spirtos N, Herzog TJ, Sabbatini P, Armstrong DK, Kim B, Fujiwara K, Walker JL, Flynn PJ, Secord AA, Cohn DE, Brady MF, Mannel RS. A phase III randomized controlled trial of secondary surgical cytoreduction (SSC) followed by platinum-based combination chemotherapy (PBC), with or without bevacizumab (B) in platinum-sensitive, recurrent ovarian cancer (PSOC): A NRG Oncology/Gynecologic Oncology Group (GOG) study. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 5501–5501.
Published In
Journal of Clinical Oncology
DOI
EISSN
1527-7755
ISSN
0732-183X
Publication Date
May 20, 2018
Volume
36
Issue
15_suppl
Start / End Page
5501 / 5501
Publisher
American Society of Clinical Oncology (ASCO)
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences